Literature DB >> 7489228

Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study.

M L Stefanick1, C Legault, R P Tracy, G Howard, C M Kessler, D L Lucas, T L Bush.   

Abstract

Fibrinogen levels have been reported in cohort and case-control studies to be positively related to the development of coronary heart disease. This report presents the distribution and determinants of fibrinogen in women enrolling in a 3-year randomized trial of hormone replacement therapy (HRT), the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. Fasting plasma fibrinogen levels were measured in 874 postmenopausal women, aged 45 to 65 years, who had not used HRT for at least 3.5 months. Mean (+/- SD) fibrinogen level was 2.83 +/- 0.45 g/L. There was a significant positive association between fibrinogen and age (P = .03). Significantly higher (P < .005) fibrinogen levels were seen in current smokers versus nonsmokers (2.94 versus 2.81 g/L), in women who reported consuming fewer than 12 alcoholic drinks in the 12 months before the baseline visit versus higher consumption (2.90 versus 2.79 g/L), and in women who reported never versus ever having used HRT (2.90 versus 2.77 g/L). Self-reported leisure time physical activity (LTPA) was negatively associated (P = .0001) with fibrinogen levels as follows: inactive (2.84 g/L), light (2.89 g/L), moderate (2.80 g/L), and heavy (2.60 g/L), with significantly (P = .0001) lower levels in women who reported heavy LTPA versus each of the other categories and in women reporting moderate versus light LTPA. A strong positive correlation was found between fibrinogen and body mass index (BMI) (r = .32; P < .0001). In a model that included age, smoking, alcohol intake, prior HRT, LTPA, and BMI, LTPA was no longer a statistically significant predictor of fibrinogen level, while associations with other variables remained significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489228     DOI: 10.1161/01.atv.15.12.2085

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study.

Authors:  Virginia M Miller; Tanya M Petterson; Elysia N Jeavons; Abhinita S Lnu; David N Rider; John A Heit; Julie M Cunningham; Gordon S Huggins; Howard N Hodis; Matthew J Budoff; Nanette Santoro; Paul N Hopkins; Rogerio A Lobo; JoAnn E Manson; Frederick Naftolin; Hugh S Taylor; S Mitchell Harman; Mariza de Andrade
Journal:  Physiol Genomics       Date:  2012-11-27       Impact factor: 3.107

2.  A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study.

Authors:  A Tybjaerg-Hansen; B Agerholm-Larsen; S E Humphries; S Abildgaard; P Schnohr; B G Nordestgaard
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 3.  Vascular effects of estrogenic menopausal hormone therapy.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Rev Recent Clin Trials       Date:  2012-02

4.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

Review 5.  Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms.

Authors:  Cullen O'Gorman; Robyn Lucas; Bruce Taylor
Journal:  Int J Mol Sci       Date:  2012-09-18       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.